Elexacaftor, Tezacaftor and Ivacator [Trikafta]

Cystic Fibrosis
Patent oppositions filed in

Tricafta is a combination of 3 CFTR drugs Elexacaftor, Tezacaftor and Ivacator. Trikafta is found to help the protein of CFTR gene mutation to function effectively thereby making it an effective therapy option for majority of CF patients.

This drug is missing the following documents, can you help us by contributing something?


Information related to relevant oppositions from around the world.

Patent Oppositions

The table includes oppositions aimed at contesting patents covering this drug. Note that at the country level, several patent applications can cover the same drug.

Please pay attention not only to the patent opposition, but also to the patent application it relates to, see column "Related Patent Application". To better identify similarities, the column "Patent Type" indicates a general classification of the patent. Arguments used to contest a specific type of patent may apply for another that fits in the same category.

CountryDateWho FiledOpposition typeOpposition statusPatent typeRelated patent applicationMore info
India15-03-2021G. Srinivasa RaoPre-GrantUnder ExaminationCombination201737015848View/Comment
India04-12-2023Balaji RPre-GrantUnder ExaminationMolecules201737015848View/Comment

Is something missing? Help us by contributing missing data: Contribute

↑ Back to Top